id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2007-D-0369-0431,FDA,FDA-2007-D-0369,"Product-Specific Guidance for Methylphenidate Hydrochloride; New
Draft Guidance for Industry; Availability",Notice,Notice of Availability,2017-10-23T04:00:00Z,2017,10,2017-10-23T04:00:00Z,2017-12-23T04:59:59Z,2017-10-23T14:27:17Z,2017-22891,0,0,0900006482bf72d7
FDA-2007-D-0369-0430,FDA,FDA-2007-D-0369,"Product-Specific Guidances for Salmeterol Xinafoate and Fluticasone
Propionate; Draft Guidances for Industry; Availability",Notice,Notice of Availability,2017-10-20T04:00:00Z,2017,10,2017-10-20T04:00:00Z,2017-12-20T04:59:59Z,2017-10-20T13:54:10Z,2017-22735,0,0,0900006482be9217
FDA-2007-D-0369-0429,FDA,FDA-2007-D-0369,"Product-Specific Guidances; Draft and Revised Draft Guidances for Industry;
Availability",Notice,Notice of Availability,2017-10-20T04:00:00Z,2017,10,2017-10-20T04:00:00Z,2017-12-20T04:59:59Z,2017-12-20T02:03:13Z,2017-22736,0,0,0900006482be91d2
FDA-2007-D-0369-0428,FDA,FDA-2007-D-0369,Product-Specific Guidance for Tiotropium Bromide; Draft Guidance for Industry; Availability,Notice,Notice of Availability,2017-10-20T04:00:00Z,2017,10,2017-10-20T04:00:00Z,2017-12-20T04:59:59Z,2017-12-20T02:03:36Z,2017-22734,0,0,0900006482be9196
FDA-2007-D-0369-0423,FDA,FDA-2007-D-0369,"Product-Specific Guidance for Digoxin; Draft Revised Guidance for Industry;
Availability",Notice,Notice of Availability,2017-08-30T04:00:00Z,2017,8,2017-08-30T04:00:00Z,2017-10-31T03:59:59Z,2024-11-07T01:10:58Z,2017-18386,1,0,0900006482af3e42
FDA-2007-D-0369-0421,FDA,FDA-2007-D-0369,Product-Specific Guidances; Final Guidances for Industry; Availability,Notice,Notice of Availability,2017-08-07T04:00:00Z,2017,8,2017-08-07T04:00:00Z,,2017-08-07T14:53:59Z,2017-16581,0,0,09000064829c5600
FDA-2007-D-0369-0418,FDA,FDA-2007-D-0369,Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,Notice,Notice of Availability,2017-07-14T04:00:00Z,2017,7,2017-07-14T04:00:00Z,2017-09-13T03:59:59Z,2022-08-04T18:35:31Z,2017-14781,0,0,09000064829219a8
FDA-2007-D-0369-0412,FDA,FDA-2007-D-0369,"Product-Specific Guidances; Draft and Revised Draft Guidances for 
Industry; Availability",Notice,Notice of Availability,2017-05-17T04:00:00Z,2017,5,2017-05-17T04:00:00Z,2017-07-18T03:59:59Z,2017-09-06T01:03:54Z,2017-09961,0,0,09000064825cf1ee
FDA-2007-D-0369-0409,FDA,FDA-2007-D-0369,Product-Specific Guidance for Naloxone Hydrochloride; New Draft  Guidance for Industry; Availability,Notice,Notice of Availability,2017-04-24T04:00:00Z,2017,4,2017-04-24T04:00:00Z,2017-06-24T03:59:59Z,2017-06-17T13:02:02Z,2017-08199,0,0,090000648256cde8
FDA-2007-D-0369-0407,FDA,FDA-2007-D-0369,Draft Guidance on Rifaximin re Product-Specific Guidances for Rifaximin; Revised Draft Guidance for Industry; Availability,Other,Guidance,2017-03-16T04:00:00Z,2017,3,2017-03-16T04:00:00Z,,2024-11-07T00:56:39Z,,1,0,090000648250ca6d
FDA-2007-D-0369-0406,FDA,FDA-2007-D-0369,"Product-Specific Guidances for Rifaximin; Revised Draft Guidance for
Industry; Availability",Notice,Notice of Availability,2017-03-16T04:00:00Z,2017,3,2017-03-16T04:00:00Z,2017-05-16T03:59:59Z,2017-05-16T01:01:05Z,2017-05245,0,0,090000648250c619
FDA-2007-D-0369-0403,FDA,FDA-2007-D-0369,Bioequivalence Recommendations for Difluprednate; Revised Draft Guidance for Industry; Availability,Notice,Notice of Availability,2017-02-15T05:00:00Z,2017,2,2017-02-15T05:00:00Z,2017-04-18T03:59:59Z,2017-02-23T16:47:31Z,2017-02972,0,0,09000064824c2630
FDA-2007-D-0369-0402,FDA,FDA-2007-D-0369,Supplemental Comment from Mylan,Other,Supplemental Comment,2017-02-09T05:00:00Z,2017,2,2017-02-09T05:00:00Z,,2017-02-09T17:38:45Z,,0,0,09000064824b6f72